Brentuximab vedotin enables successful reduced-intensity allogeneic hematopoietic cell transplantation in patients with relapsed or refractory Hodgkin lymphoma.
暂无分享,去创建一个
A. Nademanee | S. Forman | Robert Chen | A. Gopal | Sandra H. Thomas | N. Tsai | J. Palmer | L. Farol | Robert Chen